{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:44:39Z","timestamp":1784904279834,"version":"3.55.0"},"reference-count":208,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Standard cancer chemotherapy is increasingly being supplemented with novel therapeutics to overcome known chemoresistance pathways. Resistance to treatment is common across various tumour types, driven by multiple mechanisms. One emerging contributor is protein methylation, a post-translational modification mediated by protein methyltransferases (PMTs), which regulate protein function by adding methyl groups, mainly on lysine and arginine residues. Dysregulation of protein lysine methyltransferases (PKMTs) and protein arginine methyltransferases (PRMTs) has been linked to cancer progression and drug resistance, making them attractive therapeutic targets. Consequently, several small-molecule PMT inhibitors have been developed, with some progressing to clinical trials. However, many candidates showing promise in preclinical studies fail to demonstrate efficacy or safety in later stages, limiting clinical success. This gap highlights the need to rethink current approaches to PMT inhibitor design. A deeper understanding of PMT mechanisms, catalytic domains, and their roles in chemoresistance is essential for creating more selective, potent, and clinically viable inhibitors. This review will summarise major chemoresistance pathways and PMTs implicated in cancer, then explore current and prospective PMT inhibitor classes. Building on mechanistic insights, we propose strategies to develop next-generation inhibitors with improved therapeutic potential against chemoresistant cancers.<\/jats:p>","DOI":"10.3390\/ijms26189038","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T08:03:47Z","timestamp":1758096227000},"page":"9038","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Therapeutic Targeting of Protein Lysine and Arginine Methyltransferases: Principles and Strategies for Inhibitor Design"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4602-1400","authenticated-orcid":false,"given":"Isaac","family":"Micallef","sequence":"first","affiliation":[{"name":"Department of Tumor Genetics and Biology, Graduate School of Medical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan"},{"name":"Centre for Molecular Medicine and Biobanking, University of Malta, MSD 2080 Msida, Malta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5722-6295","authenticated-orcid":false,"given":"Byron","family":"Baron","sequence":"additional","affiliation":[{"name":"Centre for Molecular Medicine and Biobanking, University of Malta, MSD 2080 Msida, Malta"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.15171\/apb.2017.041","article-title":"The different mechanisms of cancer drug resistance: A brief review","volume":"7","author":"Mansoori","year":"2017","journal-title":"Adv. Pharm. Bull."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s12032-023-02138-y","article-title":"Cancer chemoresistance and its mechanisms: Associated molecular factors and its regulatory role","volume":"40","author":"Kannampuzha","year":"2023","journal-title":"Med. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12964-023-01302-1","article-title":"Unveiling the mechanisms and challenges of cancer drug resistance","volume":"22","author":"Khan","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"ref_4","first-page":"161","article-title":"Effects of DNA topoisomerase II\u03b1 splice variants on acquired drug resistance","volume":"3","author":"Elton","year":"2020","journal-title":"Cancer Drug Resist."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non\u2013small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.4155\/fmc-2018-0200","article-title":"Overcoming the emerging drug resistance of smoothened: An overview of small-molecule SMO antagonists with antiresistance activity","volume":"10","author":"Zhang","year":"2018","journal-title":"Futur. Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/sj.leu.2402114","article-title":"Nucleoside analogues: Mechanisms of drug resistance and reversal strategies","volume":"15","author":"Galmarini","year":"2001","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7524","DOI":"10.1038\/sj.onc.1206952","article-title":"Nucleoside anticancer drugs: The role of nucleoside transporters in resistance to cancer chemotherapy","volume":"22","author":"Damaraju","year":"2003","journal-title":"Oncogene"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"118907","DOI":"10.1016\/j.lfs.2020.118907","article-title":"The effects of drug transporters on the efficacy of methotrexate in the treatment of rheumatoid arthritis","volume":"268","author":"Gao","year":"2021","journal-title":"Life Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/bjc.2016.203","article-title":"ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel-and olaparib-resistant ovarian cancer cells","volume":"115","author":"Vaidyanathan","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1158\/1535-7163.MCT-07-0397","article-title":"Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells","volume":"7","author":"Hui","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.drudis.2021.09.020","article-title":"Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects","volume":"27","author":"Mirzaei","year":"2022","journal-title":"Drug Discov. Today"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"98","DOI":"10.5483\/BMBRep.2018.51.2.222","article-title":"Drug resistance of bladder cancer cells through activation of ABCG2 by FOXM1","volume":"51","author":"Roh","year":"2018","journal-title":"BMB Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1002\/jcp.26406","article-title":"Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis","volume":"233","author":"Hsu","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Kim, E.J., Kim, Y.J., Lee, H.I., Jeong, S.H., Nam, H.J., and Cho, J.H. (2020). NRF2 knockdown resensitizes 5-fluorouracil-resistant pancreatic cancer cells by suppressing HO-1 and ABCG2 expression. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21134646"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/cbf.3577","article-title":"Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer","volume":"39","author":"Chen","year":"2021","journal-title":"Cell Biochem. Funct."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Biswas, R., Bugde, P., He, J., Merien, F., Lu, J., Liu, D.X., Myint, K., Liu, J., McKeage, M., and Li, Y. (2019). Transport-mediated oxaliplatin resistance associated with endogenous overexpression of MRP2 in Caco-2 and PANC-1 cells. Cancers, 11.","DOI":"10.3390\/cancers11091330"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Pljesa-Ercegovac, M., Savic-Radojevic, A., Matic, M., Coric, V., Djukic, T., Radic, T., and Simic, T. (2018). Glutathione transferases: Potential targets to overcome chemoresistance in solid tumors. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19123785"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"73347","DOI":"10.18632\/oncotarget.12332","article-title":"Promoter methylation patterns of ABCB1, ABCC1 and ABCG2 in human cancer cell lines, multidrug-resistant cell models and tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients","volume":"7","author":"Spitzwieser","year":"2016","journal-title":"Oncotarget"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/iep.12212","article-title":"Hypermethylation of ATP-binding cassette B1 (ABCB 1) multidrug resistance 1 (MDR 1) is associated with cisplatin resistance in the A549 lung adenocarcinoma cell line","volume":"97","author":"Li","year":"2016","journal-title":"Int. J. Exp. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.bbrc.2020.03.114","article-title":"Genetic and epigenetic aberrations of ABCB1 synergistically boost the acquisition of taxane resistance in esophageal squamous cancer cells","volume":"526","author":"Sumarpo","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ncrna.2021.12.001","article-title":"microRNAs in cancer chemoresistance: The sword and the shield","volume":"6","author":"Mondal","year":"2021","journal-title":"Non-Coding RNA Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1080\/17425255.2016.1215423","article-title":"ATP-binding cassette transmembrane transporters and their epigenetic control in cancer: An overview","volume":"12","author":"Arrigoni","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Shui, X., Tian, L., Zhou, Y., and Zhao, B. (2024). Targeting ACSS2 activity suspends the formation of chemoresistance through suppressed histone H3 acetylation in human breast cancer. Res. Sq.","DOI":"10.21203\/rs.3.rs-3964435\/v1"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00280-016-2979-9","article-title":"Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription","volume":"77","author":"Ye","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.biopha.2017.07.035","article-title":"Regulatory players of DNA damage repair mechanisms: Role in cancer chemoresistance","volume":"93","author":"Sakthivel","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.canlet.2020.01.008","article-title":"DNA damage response and resistance of cancer stem cells","volume":"474","author":"Abad","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Li, L.Y., Guan, Y.D., Chen, X.S., Yang, J.M., and Cheng, Y. (2021). DNA repair pathways in cancer therapy and resistance. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.629266"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/1440-1681.12581","article-title":"Molecular mechanisms for tumour resistance to chemotherapy","volume":"43","author":"Pan","year":"2016","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Alimbetov, D., Askarova, S., Umbayev, B., Davis, T., and Kipling, D. (2018). Pharmacological targeting of cell cycle, apoptotic and cell adhesion signaling pathways implicated in chemoresistance of cancer cells. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19061690"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Chen, L., Zeng, Y., and Zhou, S.F. (2018). Role of apoptosis in cancer resistance to chemotherapy. Current Understanding of Apoptosis\u2014Programmed Cell Death, IntechOpen.","DOI":"10.5772\/intechopen.80056"},{"key":"ref_32","first-page":"647","article-title":"Computational prediction of methylation types of covalently modified lysine and arginine residues in proteins","volume":"18","author":"Deng","year":"2017","journal-title":"Brief Bioinform."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Cloutier, P., Lavall\u00e9e-Adam, M., Faubert, D., Blanchette, M., and Coulombe, B. (2013). A Newly Uncovered Group of Distantly Related Lysine Methyltransferases Preferentially Interact with Molecular Chaperones to Regulate Their Activity. PLoS Genet., 9.","DOI":"10.1371\/journal.pgen.1003210"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.tibs.2013.02.004","article-title":"Protein methylation at the surface and buried deep: Thinking outside the histone box","volume":"38","author":"Clarke","year":"2013","journal-title":"Trends Biochem. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrg3173","article-title":"Histone methylation: A dynamic mark in health, disease and inheritance","volume":"13","author":"Greer","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Copeland, R.A. (2018). Protein methyltransferase inhibitors as precision cancer therapeutics: A decade of discovery. Philos. Trans. R. Soc. B Biol. Sci., 373.","DOI":"10.1098\/rstb.2017.0080"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2174\/1389203721666200507091952","article-title":"Non-histone arginine methylation by protein arginine methyltransferases","volume":"21","author":"Diaz","year":"2020","journal-title":"Curr. Protein Pept. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/tcr.201800082","article-title":"Mechanisms and inhibitors of histone arginine methylation","volume":"18","author":"Fulton","year":"2018","journal-title":"Chem. Rec."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1021\/cb500785t","article-title":"Chemical probes of histone lysine methyltransferases","volume":"10","author":"Kaniskan","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1021\/jm501234a","article-title":"Selective inhibitors of protein methyltransferases","volume":"58","author":"Kaniskan","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4161\/cc.27353","article-title":"Protein arginine methylation of non-histone proteins and its role in diseases","volume":"13","author":"Wei","year":"2014","journal-title":"Cell Cycle"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1007\/s00018-017-2515-z","article-title":"Protein arginine methylation: A prominent modification and its demethylation","volume":"74","author":"Wesche","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.compbiolchem.2014.01.009","article-title":"Identification and characterization of lysine-methylated sites on histones and non-histone proteins","volume":"50","author":"Lee","year":"2014","journal-title":"Comput. Biol. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1007\/s00018-015-2001-4","article-title":"Emerging roles of lysine methylation on non-histone proteins","volume":"72","author":"Zhang","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc3884","article-title":"Critical roles of non-histone protein lysine methylation in human tumorigenesis","volume":"15","author":"Hamamoto","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.bbagrm.2014.02.008","article-title":"An unexpected journey: Lysine methylation across the proteome","volume":"1839","author":"Moore","year":"2014","journal-title":"Biochim. Biophys. Acta (BBA) Gene Regul. Mech."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrm3915","article-title":"Non-histone protein methylation as a regulator of cellular signalling and function","volume":"16","author":"Biggar","year":"2015","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1096\/fj.01-0401rev","article-title":"S-adenosylmethionine: A control switch that regulates liver function","volume":"16","author":"Mato","year":"2002","journal-title":"FASEB J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1021\/bi035611t","article-title":"Crystal structure of the S-adenosylmethionine synthetase ternary complex: A novel catalytic mechanism of S-adenosylmethionine synthesis from ATP and Met","volume":"43","author":"Komoto","year":"2004","journal-title":"Biochemistry"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Hao, X., Huang, Y., Qiu, M., Yin, C., Ren, H., Gan, H., Li, H., Zhou, Y., Xia, J., and Li, W. (2016). Immunoassay of S-adenosylmethionine and S-adenosylhomocysteine: The methylation index as a biomarker for disease and health status. BMC Res. Notes, 9.","DOI":"10.1186\/s13104-016-2296-8"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Pascale, R.M., Simile, M.M., Calvisi, D.F., Feo, C.F., and Feo, F. (2022). S-adenosylmethionine: From the discovery of its inhibition of tumorigenesis to its use as a therapeutic agent. Cells, 11.","DOI":"10.3390\/cells11030409"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.gene.2013.09.063","article-title":"Folate: Metabolism, genes, polymorphisms and the associated diseases","volume":"533","author":"Nazki","year":"2014","journal-title":"Gene"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/jimd.12009","article-title":"Vitamin B12, folate, and the methionine remethylation cycle-biochemistry, pathways, and regulation","volume":"42","author":"Froese","year":"2019","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1042\/BST0340330","article-title":"S-Adenosylmethionine: Jack of all trades and master of everything?","volume":"34","author":"Loenen","year":"2006","journal-title":"Biochem. Soc. Trans."},{"key":"ref_55","first-page":"1212","article-title":"Effects of S-adenosyl-L-methionine on the invasion and migration of head and neck squamous cancer cells and analysis of the underlying mechanisms","volume":"56","author":"Mosca","year":"2020","journal-title":"Int. J. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"111866","DOI":"10.18632\/oncotarget.22942","article-title":"S-adenosyl-methionine (SAM) alters the transcriptome and methylome and specifically blocks growth and invasiveness of liver cancer cells","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Mosca, L., Pagano, M., Borzacchiello, L., Mele, L., Russo, A., Russo, G., Cacciapuoti, G., and Porcelli, M. (2021). S-adenosylmethionine increases the sensitivity of human colorectal cancer cells to 5-fluorouracil by inhibiting P-glycoprotein expression and NF-\u03baB activation. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22179286"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Fern\u00e1ndez-Ramos, D., Lopitz-Otsoa, F., Lu, S.C., and Mato, J.M. (2025). S-adenosylmethionine: A multifaceted regulator in cancer pathogenesis and therapy. Cancers, 17.","DOI":"10.3390\/cancers17030535"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1747-0285.2011.01135.x","article-title":"Chemogenetic analysis of human protein methyltransferases","volume":"78","author":"Richon","year":"2011","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1021\/acs.chemrev.6b00801","article-title":"Inhibitors of protein methyltransferases and demethylases","volume":"118","author":"Kaniskan","year":"2018","journal-title":"Chem. Rev."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1472-6807-5-19","article-title":"Natural history of S-adenosylmethionine-binding proteins","volume":"5","author":"Kozbial","year":"2005","journal-title":"BMC Struct. Biol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41594-019-0298-7","article-title":"Histone lysine methyltransferases in biology and disease","volume":"26","author":"Hamamoto","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1039\/C4MD00269E","article-title":"Structural biology and chemistry of protein arginine methyltransferases","volume":"5","author":"Schapira","year":"2014","journal-title":"Medchemcomm"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"M110.000976","DOI":"10.1074\/mcp.M110.000976","article-title":"Uncovering the human methyltransferasome","volume":"10","author":"Petrossian","year":"2011","journal-title":"Mol. Cell Proteom."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Tkaczuk, K.L., Dunin-Horkawicz, S., Purta, E., and Bujnicki, J.M. (2007). Structural and evolutionary bioinformatics of the SPOUT superfamily of methyltransferases. BMC Bioinform., 8.","DOI":"10.1186\/1471-2105-8-73"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1021\/bi300186g","article-title":"Identification of methylated proteins in the yeast small ribosomal subunit: A role for SPOUT methyltransferases in protein arginine methylation","volume":"51","author":"Young","year":"2012","journal-title":"Biochemistry"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"a026435","DOI":"10.1101\/cshperspect.a026435","article-title":"Nonhistone lysine methylation in the regulation of cancer pathways","volume":"6","author":"Carlson","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc3409","article-title":"Protein arginine methyltransferases and cancer","volume":"13","author":"Yang","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.cell.2007.10.039","article-title":"New Nomenclature for Chromatin-Modifying Enzymes","volume":"131","author":"Allis","year":"2007","journal-title":"Cell"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/abbs\/gmr100","article-title":"Lysine methylation: Beyond histones","volume":"44","author":"Zhang","year":"2012","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1146\/annurev.biophys.34.040204.144452","article-title":"Structural and sequence motifs of protein (histone) methylation enzymes","volume":"34","author":"Cheng","year":"2005","journal-title":"Annu. Rev. Biophys. Biomol. Struct."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1042\/BCJ20160117","article-title":"Protein lysine methylation by seven-\u03b2-strand methyltransferases","volume":"473","author":"Falnes","year":"2016","journal-title":"Biochem. J."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2015.01.002","article-title":"Targeting histone lysine methylation in cancer","volume":"150","author":"McGrath","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Wood, K., Tellier, M., and Murphy, S. (2018). DOT1L and H3K79 methylation in transcription and genomic stability. Biomolecules, 8.","DOI":"10.3390\/biom8010011"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5309","DOI":"10.1093\/molbev\/msab267","article-title":"Evolution of methyltransferase-like (METTL) proteins in metazoa: A complex gene family involved in epitranscriptomic regulation and other epigenetic processes","volume":"38","author":"Wong","year":"2021","journal-title":"Mol. Biol. Evol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Falnes, P.\u00d8., Ma\u0142ecki, J.M., Herrera, M.C., Bengtsen, M., and Davydova, E. (2023). Human seven-\u03b2-strand (METTL) methyltransferases-conquering the universe of protein lysine methylation. J. Biol. Chem., 299.","DOI":"10.1016\/j.jbc.2023.104661"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1016\/j.molcel.2021.09.011","article-title":"Cellular pathways influenced by protein arginine methylation: Implications for cancer","volume":"81","author":"Xu","year":"2021","journal-title":"Mol. Cell"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1007\/s00018-019-03145-x","article-title":"Protein arginine methyltransferases: Insights into the enzyme structure and mechanism at the atomic level","volume":"76","author":"Tewary","year":"2019","journal-title":"Cell Mol. Life Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1038\/ncomms7428","article-title":"PRMT9 is a type II methyltransferase that methylates the splicing factor SAP145","volume":"6","author":"Yang","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/jcmm.14036","article-title":"Targeting PRMT5\/Akt signalling axis prevents human lung cancer cell growth","volume":"23","author":"Zhang","year":"2019","journal-title":"J. Cell. Mol. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.7150\/jca.23835","article-title":"Protein arginine methyltransferase 8 gene enhances the colon cancer stem cell (CSC) function by upregulating the pluripotency transcription factor","volume":"9","author":"Lin","year":"2018","journal-title":"J. Cancer"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1111\/jcmm.16260","article-title":"Protein arginine methyltransferase 5 (PRMT5) activates WNT\/\u03b2-catenin signalling in breast cancer cells via epigenetic silencing of DKK1 and DKK3","volume":"25","author":"Shailesh","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Chai, H., Pan, C., Zhang, M., Huo, H., Shan, H., and Wu, J. (2023). Histone methyltransferase SETD1A interacts with notch and promotes notch transactivation to augment ovarian cancer development. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-10573-3"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.canlet.2020.05.029","article-title":"Blocking histone methyltransferase SETDB1 inhibits tumorigenesis and enhances cetuximab sensitivity in colorectal cancer","volume":"487","author":"Hou","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13148-020-00897-3","article-title":"Clinicopathologic significance of protein lysine methyltransferases in cancer","volume":"12","author":"Vougiouklakis","year":"2020","journal-title":"Clin. Epigenet."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Ning, J., Chen, L., Xiao, G., Zeng, Y., Shi, W., Tanzhu, G., and Zhou, R. (2023). The protein arginine methyltransferase family (PRMTs) regulates metastases in various tumors: From experimental study to clinical application. Biomed. Pharmacother., 167.","DOI":"10.1016\/j.biopha.2023.115456"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1021\/ci100479z","article-title":"Structural chemistry of the histone methyltransferases cofactor binding site","volume":"51","author":"Mok","year":"2011","journal-title":"J. Chem. Inf. Model."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1021\/cb300139y","article-title":"A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma","volume":"7","author":"Yuan","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"7669","DOI":"10.1021\/acs.jmedchem.9b00112","article-title":"Selective, small-molecule co-factor binding site inhibition of a Su (var) 3\u20139, enhancer of zeste, trithorax domain containing lysine methyltransferase","volume":"62","author":"Taylor","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1080\/17568919.2024.2380243","article-title":"Dual-target EZH2 inhibitor: Latest advances in medicinal chemistry","volume":"16","author":"Wei","year":"2024","journal-title":"Futur. Med. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s13318-017-0404-3","article-title":"Preclinical pharmacokinetics and pharmacodynamics of pinometostat (EPZ-5676), a first-in-class, small molecule S-adenosyl methionine competitive inhibitor of DOT1L","volume":"42","author":"Waters","year":"2017","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.bmcl.2019.03.042","article-title":"Nucleoside protein arginine methyltransferase 5 (PRMT5) inhibitors","volume":"29","author":"Lin","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Ferreira de Freitas, R., Ivanochko, D., and Schapira, M. (2019). Methyltransferase inhibitors: Competing with, or exploiting the bound cofactor. Molecules, 24.","DOI":"10.3390\/molecules24244492"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"8931","DOI":"10.1021\/jm401480r","article-title":"Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP","volume":"56","author":"Liu","year":"2013","journal-title":"J. Med. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/cmdc.201300450","article-title":"A chemical tool for in vitro and in vivo precipitation of lysine methyltransferase G9a","volume":"9","author":"Konze","year":"2014","journal-title":"ChemMedChem"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1021\/ml400496h","article-title":"Discovery and development of potent and selective inhibitors of histone methyltransferase g9a","volume":"5","author":"Sweis","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1016\/j.ymthe.2024.05.034","article-title":"Newly developed oral bioavailable EHMT2 inhibitor as a potential epigenetic therapy for Prader-Willi syndrome","volume":"32","author":"Wang","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1021\/cb400133j","article-title":"An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1","volume":"8","author":"Konze","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"9928","DOI":"10.1021\/acs.jmedchem.6b01315","article-title":"Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1, 2-dihydropyridin-3-yl) methyl)-2-methyl-1-(1-(1-(2, 2, 2-trifluoroethyl) piperidin-4-yl) ethyl)-1 H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas","volume":"59","author":"Vaswani","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1021\/acs.jmedchem.7b01375","article-title":"Optimization of orally bioavailable enhancer of zeste homolog 2 (EZH2) inhibitors using ligand and property-based design strategies: Identification of development candidate (R)-5, 8-Dichloro-7-(methoxy (oxetan-3-yl) methyl)-2-((4-methoxy-6-methyl-2-oxo-1, 2-dihydropyridin-3-yl) methyl)-3, 4-dihydroisoquinolin-1 (2 H)-one (PF-06821497)","volume":"61","author":"Kung","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1021\/acsmedchemlett.7b00437","article-title":"Discovery of EBI-2511: A highly potent and orally active EZH2 inhibitor for the treatment of non-hodgkin\u2019s lymphoma","volume":"9","author":"Lu","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"12853","DOI":"10.1073\/pnas.1407358111","article-title":"(R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells","volume":"111","author":"Li","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1021\/acs.jmedchem.5b01732","article-title":"Identification of cyproheptadine as an inhibitor of SET domain containing lysine methyltransferase 7\/9 (Set7\/9) that regulates estrogen-dependent transcription","volume":"59","author":"Takemoto","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1021\/acs.jmedchem.5b01890","article-title":"Discovery and characterization of a highly potent and selective aminopyrazoline-based in vivo probe (BAY-598) for the protein lysine methyltransferase SMYD2","volume":"59","author":"Eggert","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1021\/acsmedchemlett.5b00272","article-title":"Novel oxindole sulfonamides and sulfamides: EPZ031686, the first orally bioavailable small molecule SMYD3 inhibitor","volume":"7","author":"Mitchell","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1021\/acsmedchemlett.5b00124","article-title":"Discovery of A-893, a new cell-active benzoxazinone inhibitor of lysine methyltransferase SMYD2","volume":"6","author":"Sweis","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Thomenius, M.J., Totman, J., Harvey, D., Mitchell, L.H., Riera, T.V., Cosmopoulos, K., Grassian, A.R., Klaus, C., Foley, M., and Admirand, E.A. (2018). Small molecule inhibitors and CRISPR\/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0197372"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/jcp.24975","article-title":"A SMYD3 small-molecule inhibitor impairing cancer cell growth","volume":"230","author":"Peserico","year":"2015","journal-title":"J. Cell. Physiol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1158\/1538-7445.AM2018-1646","article-title":"Abstract 1646: Discovery and characterization of BAY-6035, a novel benzodiazepine-based SMYD3 inhibitor","volume":"78","author":"Gradl","year":"2018","journal-title":"Cancer Res."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"6822","DOI":"10.1021\/jm500871s","article-title":"Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8","volume":"57","author":"Ma","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1021\/cb500515r","article-title":"Small-Molecule Inhibitors of SETD8 with Cellular Activity","volume":"9","author":"Blum","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"9881","DOI":"10.1021\/acs.jmedchem.6b01244","article-title":"Structure-based design of a covalent inhibitor of the SET domain-containing protein 8 (SETD8) lysine methyltransferase","volume":"59","author":"Butler","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Gerhart, S.V., Kellner, W.A., Thompson, C., Pappalardi, M.B., Zhang, X.P., de Oca, R.M., Penebre, E., Duncan, K., Boriack-Sjodin, A., and Le, B. (2018). Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-28002-y"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/nchembio.1810","article-title":"A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models","volume":"11","author":"Kuplast","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1021\/acsmedchemlett.5b00380","article-title":"Structure and property guided design in the identification of PRMT5 tool compound EPZ015666","volume":"7","author":"Duncan","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"8158","DOI":"10.1016\/j.bmc.2010.10.022","article-title":"Development of novel bisubstrate-type inhibitors of histone methyltransferase SET7\/9","volume":"18","author":"Mori","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1039\/C6MD00573J","article-title":"Discovery of decamidine as a new and potent PRMT1 inhibitor","volume":"8","author":"Zhang","year":"2017","journal-title":"MedChemComm"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood-2014-12-619783","article-title":"Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation","volume":"125","author":"Alinari","year":"2015","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1042\/BCJ20160537","article-title":"Structural basis of arginine asymmetrical dimethylation by PRMT6","volume":"473","author":"Wu","year":"2016","journal-title":"Biochem. J."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1002\/anie.201412154","article-title":"A potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3)","volume":"54","author":"Kaniskan","year":"2015","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/cbic.202000736","article-title":"Discovery of an allosteric ligand binding site in SMYD3 lysine methyltransferase","volume":"22","author":"Talibov","year":"2021","journal-title":"ChemBioChem"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1039\/D1MD00274K","article-title":"An overview of the development of EED inhibitors to disable the PRC2 function","volume":"13","author":"Liu","year":"2022","journal-title":"RSC Med. Chem."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nchembio.1331","article-title":"Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer","volume":"9","author":"Kim","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nchembio.2304","article-title":"An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED","volume":"13","author":"Qi","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrd.2017.28","article-title":"Allosteric histone methyltransferase modulators block tumour growth","volume":"16","author":"Crunkhorn","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1158\/0008-5472.CAN-19-0428","article-title":"An allosteric PRC2 inhibitor targeting EED suppresses tumor progression by modulating the immune response","volume":"79","author":"Dong","year":"2019","journal-title":"Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1021\/acs.jmedchem.0c00479","article-title":"EEDi-5285: An exceptionally potent, efficacious, and orally active small-molecule inhibitor of embryonic ectoderm development","volume":"63","author":"Rej","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","article-title":"The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis","volume":"123","author":"Yokoyama","year":"2005","journal-title":"Cell"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"22357","DOI":"10.1074\/jbc.M116.752626","article-title":"Targeted disruption of the interaction between WD-40 repeat protein 5 (WDR5) and mixed lineage leukemia (MLL)\/SET1 family proteins specifically inhibits MLL1 and SETd1A methyltransferase complexes","volume":"291","author":"Shinsky","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"4997","DOI":"10.1021\/acs.jmedchem.0c00547","article-title":"Discovery of M-808 as a highly potent, covalent, small-molecule inhibitor of the Menin\u2013MLL interaction with strong in vivo antitumor activity","volume":"63","author":"Xu","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nchembio.1861","article-title":"Disrupting histone lysine methylation","volume":"11","author":"Trojer","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"113677","DOI":"10.1016\/j.ejmech.2021.113677","article-title":"Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity","volume":"223","author":"Chen","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s00018-015-1847-9","article-title":"The PRMT5 arginine methyltransferase: Many roles in development, cancer and beyond","volume":"72","author":"Stopa","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Antonysamy, S. (2017). The structure and function of the PRMT5:MEP50 complex. Macromolecular Protein Complexes, Springer.","DOI":"10.1007\/978-3-319-46503-6_7"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1016\/j.molcel.2021.07.019","article-title":"Molecular basis for substrate recruitment to the PRMT5 methylosome","volume":"81","author":"Mulvaney","year":"2021","journal-title":"Mol. Cell"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"13793","DOI":"10.1021\/acs.jmedchem.2c01000","article-title":"Discovery and biological characterization of PRMT5:MEP50 protein\u2013protein interaction inhibitors","volume":"65","author":"Asberry","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"15300","DOI":"10.1021\/acs.jmedchem.2c01273","article-title":"Development of macrocyclic PRMT5\u2013adaptor protein interaction inhibitors","volume":"65","author":"Krzyzanowski","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1021\/cr010182v","article-title":"Irreversible inhibitors of serine, cysteine, and threonine proteases","volume":"102","author":"Powers","year":"2002","journal-title":"Chem. Rev."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.2174\/1568026619666191011163410","article-title":"Targeting protein-protein interaction with covalent small-molecule inhibitors","volume":"19","author":"Li","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1021\/acs.jmedchem.8b01153","article-title":"Emerging and re-emerging warheads for targeted covalent inhibitors: Applications in medicinal chemistry and chemical biology","volume":"62","author":"Gehringer","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1039\/D2MD00112H","article-title":"Recent applications of covalent chemistries in protein\u2013protein interaction inhibitors","volume":"13","author":"Chan","year":"2022","journal-title":"RSC Med. Chem."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejmech.2018.10.010","article-title":"A road map for prioritizing warheads for cysteine targeting covalent inhibitors","volume":"160","author":"Petri","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Zhang, Q., Chen, X., Hu, X., Duan, X., Wan, G., Li, L., Feng, Q., Zhang, Y., Wang, N., and Yu, L. (2022). Covalent inhibitors of EZH2: Design, synthesis and evaluation. Biomed. Pharmacother., 147.","DOI":"10.1016\/j.biopha.2022.112617"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"10506","DOI":"10.1021\/acs.jmedchem.2c00652","article-title":"Discovery of the first-in-class G9a\/GLP covalent inhibitors","volume":"65","author":"Park","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1021\/acsmedchemlett.9b00074","article-title":"Discovery of potent and selective covalent protein arginine methyltransferase 5 (PRMT5) inhibitors","volume":"10","author":"Lin","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"5477","DOI":"10.1021\/acs.jmedchem.0c00406","article-title":"Discovery of a first-in-class protein arginine methyltransferase 6 (PRMT6) covalent inhibitor","volume":"63","author":"Shen","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"8216","DOI":"10.1039\/D2CS00387B","article-title":"Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders","volume":"51","author":"Diehl","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"6397","DOI":"10.1021\/acs.jmedchem.3c02394","article-title":"Discovery of the first-in-class G9a\/GLP PROTAC degrader","volume":"67","author":"Velez","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"18258","DOI":"10.1021\/acs.jmedchem.5c00704","article-title":"A Novel PROTAC G9a\/GLP Degrader that Inhibits, Similar to G9a siRNA, the Migration of MCF-7 Breast-Cancer Cells without Affecting Proliferation","volume":"68","author":"Mukherjee","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"13271","DOI":"10.1021\/acs.jmedchem.4c01192","article-title":"Discovery of potent and selective G9a degraders for the treatment of pancreatic cancer","volume":"67","author":"Shi","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"116154","DOI":"10.1016\/j.ejmech.2024.116154","article-title":"Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2","volume":"267","author":"Velez","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/acsptsci.2c00100","article-title":"Targeting triple-negative breast cancer by a novel proteolysis targeting chimera degrader of enhancer of zeste homolog 2","volume":"5","author":"Dale","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/s41556-022-00850-x","article-title":"EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis","volume":"24","author":"Wang","year":"2022","journal-title":"Nat. Cell Biol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"114462","DOI":"10.1016\/j.ejmech.2022.114462","article-title":"Discovery of precision targeting EZH2 degraders for triple-negative breast cancer","volume":"238","author":"Wang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"10167","DOI":"10.1021\/acs.jmedchem.1c00460","article-title":"Design, synthesis, and evaluation of VHL-based EZH2 degraders to enhance therapeutic activity against lymphoma","volume":"64","author":"Tu","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41589-019-0421-4","article-title":"Discovery of a first-in-class EZH2 selective degrader","volume":"16","author":"Ma","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1021\/acs.jmedchem.0c02234","article-title":"Design and synthesis of EZH2-based PROTACs to degrade the PRC2 complex for targeting the noncatalytic activity of EZH2","volume":"64","author":"Liu","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.chembiol.2021.08.004","article-title":"A NSD3-targeted PROTAC suppresses NSD3 and cMyc oncogenic nodes in cancer cells","volume":"29","author":"Xu","year":"2022","journal-title":"Cell Chem. Biol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"10611","DOI":"10.1021\/acs.jmedchem.2c00807","article-title":"Discovery of a first-in-class degrader for nuclear receptor binding SET domain protein 2 (NSD2) and Ikaros\/Aiolos","volume":"65","author":"Meng","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"6938","DOI":"10.1021\/acs.jmedchem.3c01765","article-title":"Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader","volume":"67","author":"Liu","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"114528","DOI":"10.1016\/j.ejmech.2022.114528","article-title":"Discovery of a potent and selective proteolysis targeting chimera (PROTAC) degrader of NSD3 histone methyltransferase","volume":"239","author":"Sun","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Legaard Andersson, J., Christensen, J., Kleine-Kohlbrecher, D., Comet, I.V., St\u00f8ier, J.F., Antoku, Y., Poljak, V., Moretti, L., Dolberg, J., and Jacso, T. (2023). Discovery of NSD2-degraders from novel and selective DEL hits. Chembiochem, 24.","DOI":"10.1002\/cbic.202300515"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"e2405963","DOI":"10.1002\/advs.202405963","article-title":"Discovery of PRMT3 degrader for the treatment of acute leukemia","volume":"11","author":"Zou","year":"2024","journal-title":"Adv. Sci."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"13973","DOI":"10.1021\/acs.jmedchem.5c01022","article-title":"Development of a Selective and Potent PRMT4 PROTAC Degrader with Efficacy against Multiple Myeloma in Vitro and in Vivo","volume":"68","author":"Ju","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"9977","DOI":"10.1021\/acs.jmedchem.0c01111","article-title":"Discovery of first-in-class protein arginine methyltransferase 5 (PRMT5) degraders","volume":"63","author":"Shen","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"8543","DOI":"10.1021\/acs.jmedchem.5c00198","article-title":"Discovery of a Potent and Selective Protein Arginine Methyltransferase 5 (PRMT5) PROTAC Degrader","volume":"68","author":"Zhong","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s13046-024-03237-y","article-title":"Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer","volume":"43","author":"Guo","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.chembiol.2019.11.006","article-title":"Degradation of polycomb repressive complex 2 with an EED-targeted bivalent chemical degrader","volume":"27","author":"Potjewyd","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.chembiol.2019.11.004","article-title":"EED-targeted PROTACs degrade EED, EZH2, and SUZ12 in the PRC2 complex","volume":"27","author":"Hsu","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1021\/acschembio.2c00804","article-title":"PROTAC linkerology leads to an optimized bivalent chemical degrader of polycomb repressive complex 2 (PRC2) components","volume":"18","author":"Bashore","year":"2023","journal-title":"ACS Chem. Biol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"10682","DOI":"10.1021\/acs.jmedchem.1c00146","article-title":"Design, synthesis, and evaluation of WD-repeat-containing protein 5 (WDR5) degraders","volume":"64","author":"Adhikari","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"eabj1578","DOI":"10.1126\/scitranslmed.abj1578","article-title":"A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models","volume":"13","author":"Yu","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1038\/s41388-022-02340-8","article-title":"Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic","volume":"41","author":"Li","year":"2022","journal-title":"Oncogene"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"16168","DOI":"10.1021\/acs.jmedchem.3c01521","article-title":"Discovery of potent and selective WDR5 proteolysis targeting chimeras as potential therapeutics for pancreatic cancer","volume":"66","author":"Yu","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: The past is prologue","volume":"21","author":"Langley","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"e202400269","DOI":"10.1002\/cmdc.202400269","article-title":"Towards the targeted protein degradation of PRMT1","volume":"19","author":"Martin","year":"2024","journal-title":"ChemMedChem"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1021\/acschembio.2c00062","article-title":"Exploring methods of targeting histone methyltransferases and their applications in cancer therapeutics","volume":"17","author":"Wang","year":"2022","journal-title":"ACS Chem. Biol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1021\/acs.jmedchem.4c02781","article-title":"Current and Emerging Approaches Targeting G9a for the Treatment of Various Diseases","volume":"68","author":"He","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1021\/acs.jmedchem.1c01208","article-title":"Fascinating transformation of SAM-competitive protein methyltransferase inhibitors from nucleoside analogues to non-nucleoside analogues","volume":"65","author":"Talukdar","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"9451","DOI":"10.1007\/s00432-023-04752-9","article-title":"Targeting the undruggable: Menin inhibitors ante portas","volume":"149","author":"Dempke","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Rossi, A., Zacchi, F., Reni, A., Rota, M., Palmerio, S., Menis, J., Zivi, A., Milleri, S., and Milella, M. (2024). Progresses and Pitfalls of Epigenetics in Solid Tumors Clinical Trials. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252111740"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"116212","DOI":"10.1016\/j.ejmech.2024.116212","article-title":"Overview of the development of protein arginine methyltransferase modulators: Achievements and future directions","volume":"267","author":"Tong","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"101016","DOI":"10.1016\/j.drup.2023.101016","article-title":"Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance","volume":"72","author":"Zhu","year":"2024","journal-title":"Drug Resist. Updat."},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Micallef, I., Fenech, K., and Baron, B. (2024). Therapeutic targeting potential of the protein lysine and arginine methyltransferases to reverse cancer chemoresistance. Front. Mol. Biosci., 11.","DOI":"10.3389\/fmolb.2024.1455415"},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Brekker, M.A., Sartawi, T., Sawatzky, T.M., Causey, C.P., Rehman, F.K., and Knuckley, B. (2022). A peptoid-based inhibitor of protein arginine methyltransferase 1 (PRMT1) induces apoptosis and autophagy in cancer cells. J. Biol. Chem., 298.","DOI":"10.1016\/j.jbc.2022.102205"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1002\/cmdc.202100296","article-title":"\u03b2-Actin Peptide-Based Inhibitors of Histidine Methyltransferase SETD3","volume":"16","author":"Hintzen","year":"2021","journal-title":"Chem. Med. Chem."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1021\/cb200519y","article-title":"Current chemical biology approaches to interrogate protein methyltransferases","volume":"7","author":"Luo","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Zeng, H., and Xu, W. (2015). Enzymatic assays of histone methyltransferase enzymes. Epigenetic Technological Applications, Academic Press.","DOI":"10.1016\/B978-0-12-801080-8.00016-8"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nchembio.2576","article-title":"How many human proteoforms are there?","volume":"14","author":"Aebersold","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1126\/science.aat1884","article-title":"Proteoforms as the next proteomics currency","volume":"359","author":"Smith","year":"2018","journal-title":"Science"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41592-024-02170-4","article-title":"Inside the chase after those elusive proteoforms","volume":"21","author":"Marx","year":"2024","journal-title":"Nat. Methods"},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Naryzhny, S. (2024). Puzzle of proteoform variety\u2014Where is a key?. Proteomes, 12.","DOI":"10.3390\/proteomes12020015"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"32646","DOI":"10.18632\/oncotarget.5066","article-title":"Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors","volume":"6","author":"Baker","year":"2015","journal-title":"Oncotarget"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/onc.2015.114","article-title":"Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors","volume":"35","author":"Gibaja","year":"2016","journal-title":"Oncogene"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1182\/blood-2017-08-804344","article-title":"Mechanisms of resistance to EZH2 inhibitors in diffuse large B-cell lymphomas","volume":"131","author":"Bisserier","year":"2018","journal-title":"Blood"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/j.molcel.2022.04.015","article-title":"NSD1 mediates antagonism between SWI\/SNF and polycomb complexes and is required for transcriptional activation upon EZH2 inhibition","volume":"82","author":"Drosos","year":"2022","journal-title":"Mol. Cell"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41417-023-00666-3","article-title":"Ribosomal S6 protein kinase 4 promotes resistance to EZH2 inhibitors in glioblastoma","volume":"30","author":"Pang","year":"2023","journal-title":"Cancer Gene Ther."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1158\/2159-8290.CD-23-0110","article-title":"Overcoming clinical resistance to EZH2 inhibition using rational epigenetic combination therapy","volume":"14","author":"Kazansky","year":"2024","journal-title":"Cancer Discov."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.cell.2018.08.058","article-title":"Targeting epigenetic crosstalk as a therapeutic strategy for EZH2-aberrant solid tumors","volume":"175","author":"Huang","year":"2018","journal-title":"Cell"},{"key":"ref_201","first-page":"1","article-title":"Comprehensive mass spectrometric investigation strategies of the human methylproteome","volume":"3","author":"Baron","year":"2021","journal-title":"J. Proteome Data Methods"},{"key":"ref_202","first-page":"16","article-title":"Proteomic strategies for methylation analysis in colorectal cancer chemoresistance","volume":"5","author":"Micallef","year":"2023","journal-title":"J. Proteome Data Methods"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1007\/s00018-019-03142-0","article-title":"Lysine methylation signaling of non-histone proteins in the nucleus","volume":"76","author":"Levy","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1016\/j.celrep.2018.05.050","article-title":"Targeting EZH2 reprograms intratumoral regulatory T cells to enhance cancer immunity","volume":"23","author":"Wang","year":"2018","journal-title":"Cell Rep."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"eade4186","DOI":"10.1126\/sciadv.ade4186","article-title":"PD-L1 methylation restricts PD-L1\/PD-1 interactions to control cancer immune surveillance","volume":"9","author":"Huang","year":"2023","journal-title":"Sci. Adv."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"C1313","DOI":"10.1152\/ajpcell.00494.2022","article-title":"RAGE potentiates EGFR signaling and interferes with the anticancer effect of gefitinib on NSCLC cells","volume":"325","author":"Liao","year":"2023","journal-title":"Am. J. Physiol.-Cell Physiol."},{"key":"ref_207","doi-asserted-by":"crossref","unstructured":"Zhang, X., Huo, X., Guo, H., and Xue, L. (2022). Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.965244"},{"key":"ref_208","doi-asserted-by":"crossref","unstructured":"O\u2019Brien, S., Butticello, M., Thompson, C., Wilson, B., Wyce, A., Mahajan, V., Kruger, R., Mohammad, H., and Fedoriw, A. (2023). Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11260-z"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/18\/9038\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:46:52Z","timestamp":1760035612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/18\/9038"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":208,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["ijms26189038"],"URL":"https:\/\/doi.org\/10.3390\/ijms26189038","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]}}}